Wednesday, August 19, 2015

Emerging Technological Trends in Regenerative Medicine

After a lovely lunch here at the SENS conference, we continue on with the Emerging Technological Trends in Regenerative Medicine track, and learn about Genome Editing with Engineered Nucleases, presented by Fyodor Urnov, Senior Scientist, Sangamo BioSciences Inc.

New antiviral medications and combination therapies tend to emerge every few years, with over 30 currently on the market. I don't even want to venture a guess as to how much money big pharma has made as a result, nor do I care to outline all of the potential side effects. Although grateful for the extended lifespan of those afflicted with HIV, I have often wondered... what if we could modify our immune system to be resistant to HIV? 

Guess what... we can. This technique has worked in six patients so far in phase II clinical trialsThe technique involves harvesting a patient's T-cells, using genome-editing techniques to disrupt the gene that controls the receptor used by HIV to infect those cells, and returning the modified cells to the patient. By editing a major co-receptor of HIV, CCR5, in CD4 T cells, rendering the CCR5 permanently dysfunctional by a zinc-finger nuclease.

The team is using the same genome-editing technique to modify hematopoietic stem cells ex vivo, with the goal of treating hemoglobinopathies such as sickle-cell anemia and transfusion-dependent beta-thalassemia.

Disease Targets for Genome Editing in Hematology
I look forward to following his teams work.

No comments:

Post a Comment